Active ingredientCarmustineCat. No. P-C057-001CAS 154-93-8Family · Pharmaceutical analytical standards
Carmustine
An alkylating agent of the nitrosourea family, developed in the 1960s within the US National Cancer Institute's anticancer programme and approved in 1977: it is used for brain tumours, lymphomas and multiple myeloma. This family brings together the active ingredient and nitrosamines.
Did you know?Since 1996 it has also come as biodegradable polymer wafers, devised by Henry Brem and Robert Langer, which the neurosurgeon leaves in the cavity after removing the tumour: the drug is released slowly right where it is needed.
Go to the active ingredient →Active ingredientCarmustineCat. No. P-C057-001CAS 154-93-8
Nitrosamine1,1,3-Tris(2-chloroethyl)-3-nitrosoureaCat. No. P-C057-004CAS 69113-01-5No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceCarmustine CRSEDQM code Y0002128Family Carmustine
ImpurityCarmustine impurity A CRSEDQM code C0580010Family CarmustineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.